Results 51 to 60 of about 2,145,607 (256)
PANoptosis in the pathogenesis of myelodysplastic syndromes
Molecular Oncology, EarlyView.PANoptosis, a combination of three types of programmed cell death, is mediated by a large protein complex called a PANoptosome. In healthy bone marrow hematopoietic cells, PANoptosis is restricted by inhibitory signaling. In MDS, bone marrow cells become sensitive to the PANoptotic stimuli due to the aberrant inactivation of inhibitory signaling or ...
Rohit Thalla +4 more
wiley +1 more source
Bounds in Competing Risks Models and the War on Cancer [PDF]
Competing risks models are fundamentally unidentified. This paper derives bounds for aspects of the underlying distributions under a number of different assumptions. These bounds are then applied to mortality data from the US.
Bo E. Honoré, Adriana Lleras-Muney
core +2 more sources
Mechanisms and therapeutic opportunities of the ribotoxic stress response in cancer
Molecular Oncology, EarlyView.Cancer cells' high translational demand creates opportunities to therapeutically target ribosome function. Ribosome stalling and collisions activate ZAKα and the ribotoxic stress response (RSR), which can trigger rapid, p53‐independent apoptosis in cancer.
Anastassiya Kim +7 more
wiley +1 more source
The importance of censoring in competing risks analysis of the subdistribution hazard
BMC Medical Research Methodology, 2017 Background The analysis of time-to-event data can be complicated by competing risks, which are events that alter the probability of, or completely preclude the occurrence of an event of interest.
Mark W. Donoghoe, Val Gebski
doaj +1 more source
BMC Medical Research Methodology, 2021 Background Royston-Parmar flexible parametric survival models (FPMs) can be fitted on either the cause-specific hazards or cumulative incidence scale in the presence of competing risks.
Sarwar I. Mozumder +2 more
doaj +1 more source
Molecular Oncology, EarlyView.High‐risk bladder cancer is typically treated with Bacillus Calmette‐Guérin (BCG), but 30–40% of patients relapse. No FDA‐ or CE‐approved biomarkers currently predict or prognosticate BCG failure. We systematically reviewed the literature and identified 72 eligible studies, revealing several promising biomarkers associated with BCG treatment response ...
Rui Ribeiro‐Pereira +7 more
wiley +1 more source
Molecular Oncology, EarlyView.In head and neck squamous cell carcinoma (HNSCC) p53 and p63 exert opposite roles on the transcription regulation of the lncRNA NEAT1. Under basal conditions, p53 levels are low and p63 represses NEAT1 expression. Upon genotoxic stress, p53 is rapidly induced, displacing p63 from the NEAT1 promoter leading to NEAT1 transcriptional activation and ...
Sara De Domenico +5 more
wiley +1 more source
Special Issue about Competing Risks and Multi-State Models
Journal of Statistical Software, 2011 There is a clear growing interest, at least in the statistical literature, in competing risks and multi-state models. With the rising interest in competing risks and multi-state models a number of software packages have been developed for the analysis of
Hein Putter
doaj
Molecular Oncology, EarlyView.Circulating microRNA profiles distinguish nonmalignant Lynch syndrome from cancer‐associated Lynch syndrome, sporadic colorectal cancer, and healthy controls. Age‐stratified analysis reveals disease‐specific regulatory states, and a six‐miRNA panel shows concordant separation in an independent colorectal tissue cohort.
Ramadhani Salum Chambuso +5 more
wiley +1 more source
Competing-risks regression in Stata 11 [PDF]
Competing-risks survival regression provides a useful alternative to Cox regression in the presence of one or more competing risks. For example, say that you are studying the time from initial treatment for cancer to recurrence of cancer in relation to ...
Roberto G. Gutierrez
core